| Kerri-Ann Millar |
Kerri-Ann Millar is currently the Chief Financial Officer at Cue Biopharma, Inc. since 2020. Prior to this, she worked as a Controller at Flexion Therapeutics, Inc. from 2014 to 2017. She completed her undergraduate degree at Boston University in 1992. |
| Frank M. Morich |
Frank M. Morich is currently the Chairman at Cue Biopharma, Inc. since 2020, the Executive Chairman at Aphaia Pharma AG since 2022, the Director at Viewpoint Molecular Targeting, Inc. since 2021, and the Independent Director at Perspective Therapeutics, Inc. since 2023. Previously, he served as the Chief Executive Officer & Director at Fujirebio Europe NV from 2005 to 2007, the Chief Executive Officer at NOXXON Pharma AG from 2008 to 2010, the President & Chief Executive Officer at Takeda A, the Deputy Chairman-Supervisory Board at MorphoSys AG from 2015 to 2020, the Chairman at Bayer HealthCare AG from 1982 to 2009, the Chairman-Executive Board & Chief Executive Officer at AM-Pharma BV, a Director at Bayer Corp., a Director at Bayer AG from 1982 to 2002, the Director & Chief Commercial Officer at Takeda Pharmaceutical Co., Ltd. from 2012 to 2014, the Director-Clinical Research at Miles, Inc. from 1982 to 1991, a Director at Innate Pharma SA from 2004 to 2010, a Director at IsoRay, Inc., a Director at Viewpoint (US) from 2021 to 2023, and a Member-Supervisory Board at Neuro3D SA. He also served as the Executive Vice President-International Operations at Takeda Pharmaceuticals International, Inc. from 2011 to 2012 and as the Chief Commercial Officer at Takeda Pharmaceuticals International AG from 2011 to 2014. Dr. Morich holds a doctorate degree from Philipps University of Marburg. |
| Anish Suri |
Anish Suri is a President & Chief Scientific Officer at Cue Biopharma, Inc. He previously worked as a Senior Director at Janssen Immunosciences, Inc. from 2015 to 2018 and as an Assistant Professor at Washington University School of Medicine from 2006 to 2007. Dr. Suri holds a doctorate degree from Washington University in St. Louis and an undergraduate degree from Angelo State University. |
| Peter Alec Kiener |
Peter Alec Kiener founded Zyngenia, Inc. in 2009, where he worked as President, Chief Executive Officer & Director from 2009 to 2013. Dr. Kiener also currently works at Resolve Therapeutics LLC, as Chairman, AbCellera Boston, Inc., as Director, Pieris Pharmaceuticals, Inc., as Independent Director from 2018, Cue Biopharma, Inc., as Independent Director from 2020, LAVA Therapeutics NV, as Non-Executive Director from 2023, Wugen, Inc., as Director, Itolerance, Inc., as Director, Intermediate Capital Group Plc (Private Equity), as Venture Partner, and Bridge Valley Ventures LLP, as Venture Partner. Dr. Kiener also formerly worked at Cereius, Inc., as Chief Executive Officer from 2019 to 2020, GT Biopharma, Inc., as Director from 2018 to 2019, Receptor BioLogix, Inc., as Director, Adheron Therapeutics, Inc., as Director, Virdante Pharmaceuticals, Inc., as Director, Viral Logic Systems Technology Corp., as Director, Bristol Myers Squibb Co., as Head-Global Research & Development from 1983 to 2001, MedImmune LLC, as Executive Vice President-Research & Development from 2001 to 2009, AstraZeneca PLC, as Executive Vice President in 2009, the University of Oxford, as Principal, the University of North Texas, as Assistant Professor from 1982 to 1983, the University of Massachusetts, as Research Associate from 1978 to 1982, Ambrx, Inc., as Chief Science Officer from 2013 to 2014, and Sucampo Pharmaceuticals LLC, as Chief Scientific Officer from 2014 to 2018. Dr. Kiener received his doctorate degree in 1978 from the University of Oxford and undergraduate degree in 1973 from the University of Lancaster. |
| Matteo Levisetti |
Matteo Levisetti's career history includes current and former positions as well as his education. Currently, he is the Chief Medical Officer at Cue Biopharma, Inc. Prior to this, he held the position of Chief Medical Officer at DNAtrix, Inc. from 2019 to 2021. Additionally, he served as the Executive Director-Clinical Development at Mirati Therapeutics, Inc. from 2016 to 2017 and as the Chief Medical Officer at Dauntless Pharmaceuticals, Inc. from 2017 to 2018. He also worked as the Global Head & VP-Translational Medicine at Roche Pharmaceuticals, Inc. Furthermore, he has experience as an Assistant Professor at Washington University School of Medicine. Dr. Levisetti obtained his doctorate degree from Pritzker School of Medicine in 1996. |
| Daniel R. Passeri |
Daniel R. Passeri is currently the Chief Executive Officer & Director at Cue Biopharma, Inc. He previously served as the Vice Chairman at Curis, Inc. from 2000 to 2016. He also held the position of Vice Chairman at Xequel Bio, Inc. Additionally, he worked as the Director-Technology Management at Boehringer Mannheim Pharmaceuticals Corp. from 1995 to 1997 and as the SVP-Corporate Development & Strategic Planning at Gene Logic, Inc. from 1997 to 2000. In 2014 and 2015, he was the Head-Technology Management & Business Development at Genomic Medicine, Inc. Mr. Passeri obtained his graduate degree from Imperial College London and his undergraduate degree from Northeastern University. He also holds a graduate degree from George Washington University Law School, which he received in 1994. |
| Frederick W. Driscoll |
Frederick W. Driscoll currently works at MEI Pharma, Inc., as Chairman from 2024, Calliditas Therapeutics AB, as Independent Non-Executive Director from 2023, Cellectar Biosciences, Inc., as Independent Director from 2017, Cue Biopharma, Inc., as Independent Director from 2018, SmartPharm Therapeutics, Inc., as Director from 2019, and NeoSoma, Inc., as Director from 2023. Mr. Driscoll also formerly worked at Oncotelic Therapeutics, Inc., as Chairman, President & Chief Executive Officer from 2000 to 2006, Genelabs Technologies, Inc., as President & Chief Executive Officer from 2008 to 2009, NantKwest, Inc., as Lead Independent Director, Cynapsus Therapeutics, Inc., as Director in 2016, Abpro Corp., as Independent Director, ImmunityBio, Inc., as Director, Novavax, Inc., as Chief Financial Officer, Treasurer & VP from 2012 to 2013, ConforMIS, Inc., as Chief Financial Officer & Treasurer from 2019 to 2020, Flexion Therapeutics, Inc., as Chief Financial Officer from 2013 to 2017, Flexion Therapeutics, Inc., as Chief Financial Officer in 2021, Instrumentation Laboratory Co., as Vice President-Finance-Americas & Controller from 1974 to 2006, Astraris, Inc., as Chief Financial Officer from 2006 to 2007, Collagenesis Corp., as Senior Vice President-Finance & Operations from 1996 to 2000, Invivyd, Inc., as Chief Financial & Accounting Officer from 2022 to 2023, and Renovacor, Inc., as Secretary, Chief Financial & Accounting Officer. Mr. Driscoll received his undergraduate degree in 1972 from Bentley University. |
| Patrick Verheyen |
Patrick Verheyen currently works at The Bioindustry Association, as Director and Cue Biopharma, Inc., as Independent Director from 2023. Mr. Verheyen also formerly worked at Cougar Biotechnology, Inc., as Director in 2009. Mr. Verheyen received his graduate degree from Katholieke Universiteit Leuven. |
| Pamela D. Garzone |
Pamela D. Garzone is an Independent Director at Cue Biopharma, Inc. and the Chief Development Officer at Anixa Biosciences, Inc. She was formerly an Assistant Professor at the University of Pittsburgh. Garzone received her graduate and doctorate degrees from the University of Pittsburgh and her undergraduate degree from Purdue University. |
